statepi home
MACS Homepage
MACS History
MACS Archives
MACS Scientific Contributions
MACS Directory
MACS Dossier
Forms
Manuscript Template
Public Data Tape
MACS study administration
MACS Forum








Manuscript Templates

  • HAART definition:

    The following is a paragraph defining HAART for the "Methods Section" of MACS publications (as of September, 2010).

    The definition of HAART was guided by the DHHS/Kaiser Panel [DHHS/Kaiser Dec. 2009] guidelines and defined as three or more antiretroviral drugs consisting of one or more PIs or one NNRTI or the NRTIs - Abacavir or Tenofovir, or an integrase or an entry inhibitor. The percentages are based on total HIV+ person-visits with available therapy data from July 1995 to March 2010. The first paragraph may be used for papers that are related to HAART.

    Specific combinations subject to the following restriction criteria include (a) two or more NRTIs with one NNRTI or with one or more PIs (87%); (b)one NNRTI co-administered with one ritonavir (RTV) boosted PI with or without NRTI (7%); (c) an abacavir or tenofovir containing regimen of three or more NRTIs in the absence of both PIs and NNRTIs (4%), (d) two or more RTV boosted PIs with or without other ARTs (1%); and (e) an integrase or entry inhibitor with a combination of two other antiretroviral drugs (1%) except for two unboosted PIs.

    Regimens containing the following combinations are not considered HAART: two or more NNRTIs, an NNRTI without a (RTV) boosted PI, unboosted atazanavir with TDF, boosted nelfinavir (NFV), and two NRTI combinations - zidovudine (AZT) + stavudine (d4T) or emtricitabine (FTC) + lamivudine (3TC).

    Enfuvirtide (T-20) or Maraviroc (Selzentry) or Ralegravir (Isenress) with two or more antiretroviral drugs except for all exclusions listed above were considered HAART.

    All other ART regimens were classified as combination therapy that did not meet the HAART definition. The three most frequent cases of combination therapy were: (a) two NRTIs without other ARTs (41%); (b) unallowable combinations of NNRTI and PI (29%) and (c) one NRTI and one PI (15%).

    The most frequent case of monotherapy was one NRTI (68%). Of the other monotherapy cases, one PI accounted for 26%; and one NNRTI accounted for 6%.

    Reference:

    DHHS/Henry J. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. November 3, 2008 revision. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.  

    Definitions:

    HAART = highly active antiretroviral therapy
    NNRTI = non-nucleoside reverse transcriptase inhibitor
    NRTI = nucleoside or nucleotide reverse transcriptase inhibitor
    PI = protease inhibitor

  • MACS acknowledgment:

    The Multicenter AIDS Cohort Study (MACS) includes the following:   Baltimore: The Johns Hopkins University Bloomberg School of Public Health: Joseph B. Margolick (Principal Investigator), Michael Plankey (Co-Principal Investigator), Barbara Crain, Adrian Dobs, Homayoon Farzadegan, Joel Gallant, Lisette Johnson-Hill, Ned Sacktor, Ola Selnes, James Shepard, Chloe Thio.   Chicago: Howard Brown Health Center, Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services: John P. Phair (Principal Investigator), Steven M. Wolinsky (Principal Investigator), Sheila Badri, Craig Conover, Maurice O'Gorman, David Ostrow, Frank Palella, Ann Ragin.   Los Angeles: University of California, UCLA Schools of Public Health and Medicine: Roger Detels (Principal Investigator), Otoniel Martínez-Maza (Co-Principal Investigator), Aaron Aronow, Robert Bolan, Elizabeth Breen, Anthony Butch, John Fahey, Beth Jamieson, Eric N. Miller, John Oishi, Harry Vinters, Barbara R. Visscher, Dorothy Wiley, Mallory Witt, Otto Yang, Stephen Young, Zuo Feng Zhang.   Pittsburgh: University of Pittsburgh, Graduate School of Public Health: Charles R. Rinaldo (Principal Investigator), Lawrence A. Kingsley (Co-Principal Investigator), James T. Becker, Ross D. Cranston, Jeremy J. Martinson, John W. Mellors, Anthony J. Silvestre, Ronald D. Stall. .   Data Coordinating Center: The Johns Hopkins University Bloomberg School of Public Health: Lisa P. Jacobson (Principal Investigator), Alvaro Muñoz (Co-Principal Investigator), Alison Abraham, Keri Althoff, Christopher Cox, Gypsyamber D’Souza, Stephen J. Gange, Elizabeth Golub, Janet Schollenberger, Eric C. Seaberg, Sol Su.   NIH: National Institute of Allergy and Infectious Diseases: Robin E. Huebner; National Cancer Institute: Geraldina Dominguez. UO1-AI-35042, UL1-RR025005, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041.   Website located at http://www.statepi.jhsph.edu/macs/macs.html.

  • Suggested alternative acknowledgment for manuscripts when MACS data have been used:

    Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS) with centers (Principal Investigators) at The Johns Hopkins Bloomberg School of Public Health (Joseph B. Margolick, Lisa P. Jacobson), Howard Brown Health Center, Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services (John P. Phair, Steven M. Wolinsky), University of California, Los Angeles (Roger Detels), and University of Pittsburgh (Charles R. Rinaldo). The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute. UO1-AI-35042, UL1-RR025005, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041.    Website located at http://www.statepi.jhsph.edu/macs/macs.html.

  • Links to author's instructions for specific journals

    -   AIDS
    -   AIDS Research and Human Retroviruses
    -   American Journal of Epidemiology
    -   Annals of Internal Medicine
    -   JAMA
    -   Journal of Acquired Immune Deficiency Syndromes
    -   Journal of Infectious Diseases
    -   Lancet
    -   New England Journal of Medicine

This page was last updated November 2011.